Multiplex Analysis of CircRNAs from Plasma Extracellular Vesicle-Enriched Samples for the Detection of Early-Stage Non-Small Cell Lung Cancer.
NSCLC
circRNAs
extracellular vesicles
liquid biopsies
lung cancer
nCounter
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
24 Sep 2022
24 Sep 2022
Historique:
received:
08
08
2022
revised:
15
09
2022
accepted:
15
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
The analysis of liquid biopsies brings new opportunities in the precision oncology field. Under this context, extracellular vesicle circular RNAs (EV-circRNAs) have gained interest as biomarkers for lung cancer (LC) detection. However, standardized and robust protocols need to be developed to boost their potential in the clinical setting. Although nCounter has been used for the analysis of other liquid biopsy substrates and biomarkers, it has never been employed for EV-circRNA analysis of LC patients. EVs were isolated from early-stage LC patients ( A combination of 500 μL of plasma input with 10 cycles of pre-amplification was selected for the rest of the study. Eight circRNAs were found upregulated in LC. Further ML analysis selected a 10-circRNA signature able to discriminate LC from controls with AUC ROC of 0.86. This study validates the use of the nCounter platform for multiplexed EV-circRNA expression studies in LC patient samples, allowing the development of prognostic signatures.
Sections du résumé
BACKGROUND
BACKGROUND
The analysis of liquid biopsies brings new opportunities in the precision oncology field. Under this context, extracellular vesicle circular RNAs (EV-circRNAs) have gained interest as biomarkers for lung cancer (LC) detection. However, standardized and robust protocols need to be developed to boost their potential in the clinical setting. Although nCounter has been used for the analysis of other liquid biopsy substrates and biomarkers, it has never been employed for EV-circRNA analysis of LC patients.
METHODS
METHODS
EVs were isolated from early-stage LC patients (
RESULTS
RESULTS
A combination of 500 μL of plasma input with 10 cycles of pre-amplification was selected for the rest of the study. Eight circRNAs were found upregulated in LC. Further ML analysis selected a 10-circRNA signature able to discriminate LC from controls with AUC ROC of 0.86.
CONCLUSIONS
CONCLUSIONS
This study validates the use of the nCounter platform for multiplexed EV-circRNA expression studies in LC patient samples, allowing the development of prognostic signatures.
Identifiants
pubmed: 36297470
pii: pharmaceutics14102034
doi: 10.3390/pharmaceutics14102034
pmc: PMC9610636
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European Union
ID : 765492
Références
BMC Med. 2017 Apr 6;15(1):75
pubmed: 28381299
Biomed Pharmacother. 2019 Sep;117:109041
pubmed: 31181445
Science. 2022 Mar 18;375(6586):eaay9040
pubmed: 35298272
J Extracell Vesicles. 2018 Mar 13;7(1):1446660
pubmed: 29696074
Curr Oncol Rep. 2018 Jul 20;20(9):70
pubmed: 30030656
Clin Exp Med. 2022 Nov;22(4):647-659
pubmed: 35089454
RNA Biol. 2019 Feb;16(2):220-232
pubmed: 30614753
Transl Lung Cancer Res. 2016 Oct;5(5):483-491
pubmed: 27826529
Cancer Lett. 2018 Jul 1;425:134-142
pubmed: 29625140
Mol Cancer. 2022 Mar 18;21(1):79
pubmed: 35303879
BMC Gastroenterol. 2020 May 6;20(1):137
pubmed: 32375666
PLoS Biol. 2019 Jul 18;17(7):e3000363
pubmed: 31318874
Br J Biomed Sci. 2019 Jan;76(1):17-23
pubmed: 30203720
Cancer Treat Res Commun. 2021;28:100412
pubmed: 34119765
Cell Res. 2015 Aug;25(8):981-4
pubmed: 26138677
Eur Rev Med Pharmacol Sci. 2019 Nov;23(21):9464-9470
pubmed: 31773684
J Extracell Vesicles. 2019 Nov 29;9(1):1697028
pubmed: 31839906
Oncotarget. 2015 May 10;6(13):10964-77
pubmed: 25844602
Methods Mol Biol. 2018;1783:105-120
pubmed: 29767359
Sci Rep. 2017 Jul 20;7(1):5998
pubmed: 28729721
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
J Cell Biochem. 2020 Jan;121(1):779-787
pubmed: 31452243
Genome Med. 2022 Jan 25;14(1):8
pubmed: 35078526
Front Mol Biosci. 2021 Sep 14;8:703640
pubmed: 34595207
Cancer Med. 2018 Jun;7(6):2783-2791
pubmed: 29722168
J Cancer Res Clin Oncol. 2015 Mar;141(3):431-41
pubmed: 25245053
Cell. 2019 Apr 4;177(2):428-445.e18
pubmed: 30951670
BMC Med Genomics. 2019 Nov 27;12(1):174
pubmed: 31775754
Cancer Res. 2019 Jan 1;79(1):263-273
pubmed: 30487137
Autophagy. 2020 Apr;16(4):659-671
pubmed: 31232177
Lab Invest. 2018 Dec;98(12):1657-1669
pubmed: 30087459
Oncotarget. 2018 Jan 11;9(6):7036-7053
pubmed: 29467948
Brain Pathol. 2021 Mar;31(2):387-392
pubmed: 33247464
Biomed Microdevices. 2020 Mar 11;22(2):23
pubmed: 32162067
Nature. 2013 Mar 21;495(7441):333-8
pubmed: 23446348
Cancer Res. 2018 Sep 15;78(18):5243-5258
pubmed: 30012670
Clin Pharmacol Ther. 2020 Apr;107(4):871-885
pubmed: 32128792
Sci Rep. 2020 Feb 27;10(1):3637
pubmed: 32108138
Nat Biotechnol. 2008 Mar;26(3):317-25
pubmed: 18278033
Biochem Biophys Res Commun. 2018 Nov 30;506(3):455-462
pubmed: 30352682
Sci Rep. 2021 Feb 12;11(1):3712
pubmed: 33580122
Acta Pharmacol Sin. 2017 Jan;38(1):110-119
pubmed: 27641735
Gene. 2019 Sep 5;712:143958
pubmed: 31278963
Nature. 2015 Jul 9;523(7559):177-82
pubmed: 26106858
Nature. 2013 Mar 21;495(7441):384-8
pubmed: 23446346
Cell Death Dis. 2017 May 25;8(5):e2829
pubmed: 28542138
BMC Cancer. 2019 Jun 19;19(1):603
pubmed: 31215484
Nucleic Acids Res. 2019 Sep 19;47(16):8755-8769
pubmed: 31269210
Mol Oncol. 2022 Jun;16(12):2367-2383
pubmed: 35060299
Curr Protoc Mol Biol. 2011 Apr;Chapter 25:Unit25B.10
pubmed: 21472696
Cancer Manag Res. 2021 Sep 21;13:7325-7337
pubmed: 34584458
Cancer Biol Ther. 2020;21(2):113-121
pubmed: 31597523
Diagnostics (Basel). 2020 Dec 23;11(1):
pubmed: 33374879
Clin Chem. 2021 Mar 1;67(3):554-563
pubmed: 33439966
PLoS One. 2017 Jan 23;12(1):e0170628
pubmed: 28114422
Nat Cell Biol. 2015 Jun;17(6):816-26
pubmed: 25985394